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Clinical review
Science, medicine, and the future
Prospecting for gold in the human genome
John Savill
Abstract
Doctors struggling with the daily problems of clinical
medicine usually have little time for molecular and
cell biology. But genetic research is producing an
explosion of knowledge which doctors will need to
understand in order to join in the ethical and financial
debates that will inevitably follow the new treatments
discovered. There may, indeed, be therapeutic gold
hidden in our genes, but the price for it could be more
than we can afford. This is the first of three articles
introducing a series which aims to convey the excite›
ment and potential power of biomedical science by
speculating how current research will impinge on
clinical management of common conditions.
Introduction
Doctors toiling at the coal face of modern managed
health care may be entitled to think that optimism and
excitement are outmoded states of mind in medicine.
But these feelings are major stimuli to ever more rapid
and profound developments in the biomedical
sciences. As a clinical scientist I can appreciate both
points of view. On one hand I am part of an exciting
programme of laboratory research into the molecular
cell biology of inflammatory disease. On the other, I
am a consultant in renal and general medicine. In
common with my clinical colleagues I struggle,
Canute›like, with a rising tide of acute admissions and
all the other joys of the ever changing NHS. But as I
plod round the medical admissions ward I feel both
excitement and optimism.
Paradoxically, my excitement is based on igno›
rance. This word is not easily applied to Nottingham’s
medical senior house officers as they clerk in patient
after patient, sifting through the differential diagnosis
to arrive at labels such as asthma, stroke, myocardial
infarction, or chronic obstructive airways disease. But
deep down I know that none of us understands the
pathogenesis of these disorders, even when the
diagnosis is clear. Whether evidence based or not, too
many of the treatments we offer address effect rather
than cause, and too few are both safe and reliable.
I feel optimism because there is now a realistic
prospect that this frustrating situation will be changed
by advances in biomedical sciences. As a “taster” this
article is accompanied by Ian Hall’s views on the future
of asthma.1 Similar approaches are being applied use›
fully to a wide range of important clinical problems. In
this article I outline a new, genome based philosophy
of the biomedical sciences which may greatly alter our
approach to disease and treatment.
From gene to function
Biology was once an almost arcadian pursuit. In what
might be termed the “pre›industrial” era of biomedical
science careful observation and classification chipped
away at the edifice of the unknown. However, advances
in molecular and cell biology have unleashed a new
investigative approach which, like a mechanised army,
is systematically crushing ignorance. The epitome of
this new biology is the human genome project (box).
By as early as 2004 scientists will have located and
determined the DNA sequence of nearly all our 90 000
or so genes. This flood of new knowledge may require
a profound revision of thinking among biomedical
investigators, funding bodies, and the pharmaceutical
and biotechnology industries. Many are now openly
discussing a systematic “big science” approach toward
determining the function of thousands of new genes—
perhaps 80% of which are expected to contribute to
the unique properties of the human brain—rather than
pursuing the “small science” of curiosity driven
research.
The human genome project promises unprec›
edented opportunities for science and medicine. The
tools already available to the biomedical community
should allow rapid exploitation of new knowledge.
Gene function could be explored in several ways. The
growing computer based science of bioinformatics
allows rapid comparison of novel genes with known
genes, prediction of the amino acid sequence of the
protein encoded, and thanks to a growing library of
three dimensional protein structures solved by nuclear
magnetic resonance or x ray crystallography, model›
ling of the three dimensional structure of the gene
product (fig 1). This information may allow us to
predict protein function. Function can also be inferred
from the temporal and spatial distribution of gene
expression in tissue samples, which is assessed by
detecting messenger RNA or protein product, or both.
I will describe these techniques in future articles.
In vitro studies can also give us an insight into gene
function. Genes are now routinely expressed in
cultured cell lines by using viral based DNA vectors
containing complementary DNA (cDNA), a piece of
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DNA artificially generated by using mature messenger
RNA as a template. Therefore, transcription of the
cDNA yields the gene’s messenger RNA. The protein
produced from the mRNA may then confer specific
and detectable functions on the “workhorse” cells used
to express the gene—for example, a new cell surface
adhesion molecule which confers capacity to bind leu›
cocytes. Furthermore, it is possible to manipulate
cDNA so that proteins are expressed in a soluble form
fused to polypeptide “tags.” This allows rapid purifica›
tion of large amounts of the protein that can be used to
raise antibodies, grow crystals for structural studies, or
probe protein function in vitro or in vivo in animal
models.
The best way to determine function, however, is to
manipulate gene expression in vivo. Gene manipu›
lation is most sophisticated in mice because we can
obtain pure and self propagating cultures of undiffer›
entiated, pluripotential murine embryonic stem cells.
Specific genes in the embryonic stem cells can be inac›
tivated. The manipulated stem cells can be injected into
blastocysts to generate chimeric animals from which
“knockouts” can be bred. This technique is becoming
ever more sophisticated, and it is possible to knock out
genes in particular cell lineages or even in adult
animals by exposing them to specific triggers. The
approach is very powerful and has already been used
to generate models of inherited diseases characterised
by loss of function such as cystic fibrosis.
From gene to treatment?
The human genome project will provide enormous
commercial opportunities for the pharmaceutical and
biotechnology industries, which have been quick to
realise the potential for new treatments. Traditional
problem driven research has produced many possible
targets for treatment, and molecular techniques have
been rapidly harnessed in the race for new compounds
with therapeutic potential. As soon as a cell surface
receptor is identified as a possible drug target scientists
can clone a family of similar receptors, express these in
cell lines, and test a vast panel of reagents for activation
or inhibition of a biological response (for example,
triggering of calcium influx into the cell). New
compounds identified by this high throughput screen›
ing approach are already in the therapeutic pipeline.
A particularly enticing prospect is that of rational
drug design based on knowledge of the three
dimensional structure of the therapeutic targets. Much
of this is sophisticated, computer based work but there
is already a craving for more structures and more
treatment targets. The three dimensional structures of
many pathologically important proteins are not yet
known, and determining them may suggest new
treatments. However, there is growing excitement
in pharmaceutical circles that the genome project
may identify new genes and proteins that have a role
in disease.
The “big science” approach would use all the tech›
niques described above to determine gene function
and identify effects that are likely to be important in
disease—for example, neurodegeneration induced by
knocking out a gene. Genetic research would, however,
need to be supplemented by screening for under or
over expression of particular genes in diseased tissue.
Once new genetic targets are identified the encoded
proteins could be expressed, the structure solved, and a
drug or gene therapy developed. This is not the pipe
dream of an out of touch enthusiast; major pharma›
ceutical companies have already invested heavily in this
thinking.
Problem driven research remains crucial
Fortunately for the constitutively curious such as
myself, but less fortunately for our patients, our
ignorance of the pathogenesis and treatment of
disease will not be eliminated by the biological steam›
roller I have described above. The least intellectually
The human genome project
• This is a global initiative which in Britain has
multimillion pound support from the Medical
Research Council, The Wellcome Trust, and industry
• Phase one, which is essentially complete, has been to
define marker regions of DNA which together consti›
tute a detailed map of the human genome. New
genes can now be localised with accuracy to tiny por›
tions of a particular chromosome
• The second phase, already far advanced in particu›
larly interesting parts of the genome, is to define the
DNA sequence of all the 90 000 plus human genes
• Success will rely heavily on automation and robotics
but most of all on bioinformatics, the computer based
science of logging and comparing DNA sequences.
Studies of non›human genomes have been particu›
larly profitable
• The rewards of the project are likely to be rich and
unpredictable. We can expect a major contribution to
understanding of the genetic basis of human disease,
but we also need comparable advances in ethics. We
may also need to revise current approaches to unrav›
elling disease pathogenesis and developing new
therapies
Fig 1 Computer model of 3D protein structure. The Der p I antigen of the house dust
mite Dermatophagoides pteronyssinus is a major allergen in asthma. This structure was
modelled on the basis of amino acid sequence and three known structures in the same
cysteine protease family. The coils represent á helices and the arrows depict â strands.
(Reproduced with permission of Oxford University Press from C M Topham et al, Protein
Engineering 1996;7:869›94)
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satisfying but most powerful reason is that it will prob›
ably be too expensive for society or commerce to ana›
lyse the effect of knocking out each of the 90 000 genes
or solve the structure of 90 000 proteins. Additionally,
the steamroller approach may be misleading. For
example, make a knockout of the immunosuppressive
cytokine transforming growth factor â1 and you
observe spontaneous and severe inflammatory
responses in the animal’s gut. However, the pro›fibrotic
properties of this cytokine are not revealed, although
these are likely to be crucial to its function. Thus, in a
surgical wound threatened by dehiscence increased
amounts of transforming growth factor â1 may be a
good thing, whereas in an inflamed lung it threatens
irreversible scarring and loss of function.
Not only does the big science approach threaten to
overlook such subtleties, it may also overlook
molecules important in therapy. For example, knock›
out mice with disrupted expression of the cytokine
interleukin 2, a potent activator of T lymphocytes,
retain near normal immune responses because other
cytokines can substitute for it. But interleukin 2 may
still have an important therapeutic role in enhancing
cytotoxic T cell responses to tumours.
Consequently, I believe that there will continue to
be an important role for investigation driven by clinical
problems and aimed at dissecting the complex patho›
genesis of disease. However, the human genome
project will minimise delay in identifying new proteins
and genes or in obtaining specific reagents. Solving a
clinical problem such as coronary artery disease will
require the coordinated efforts of different “tribes” of
investigators with complementary skills. Biochemists,
cell biologists, and molecular geneticists cannot work
in isolation from cardiologists, pathologists, and
radiologists. Clinical scientists wishing to find new
treatments will rely more and more on those with skills
in design and execution of clinical trials, while
epidemiological coups such as the Barker hypothesis
of fetal and infant programming for later coronary dis›
ease will continue to spark new lines of scientific
inquiry.
Conclusions
If we care to raise our eyes above seemingly ever lower
clinical horizons it should be apparent that we live in
exciting times. The new biology is not a flash in the
pan, a passing enthusiasm of academia, or another irri›
tation from central administration. In the next 20 to 30
years the pace of discovery will increase. It seems criti›
cal to me that doctors in every discipline should have
some knowledge of what is in store—because hard
decisions will need to be made about what is affordable
or ethical.
I thank Professor Noor Kalsheker, University of Notting›
ham, for the figure.
1 Hall IP. The future of asthma. BMJ 1997;314:45›9.
The future of asthma
Ian P Hall
Abstract
Reports in the media describing the discovery of “the
asthma gene” or “a new vaccine for asthma” may be
inaccurate and often raise patients’ hopes unjustifiably.
This article is a personal view of key areas in current
asthma research, and it examines how they may
impinge on the care of asthmatic patients in the next
decade. I have tried to explain the thinking behind
some of the approaches under study. I discuss the
potential contributions of genetic studies,
immunological approaches, and new therapeutic
approaches.
Introduction
The molecular sciences have promised so much over
recent years, but have they really delivered important
advances that have improved the way we practise clini›
cal medicine? Cynics could maintain that the main
classes of drugs used for treating asthma have been
around for over 20 years, and, despite a vast range of
potential targets in the airways having been identified,
no new major treatments have arisen as a direct conse›
quence of basic scientific research. However, I think
there is genuine reason to be excited about the
prospects for the next few years. Research in key areas
has reached a stage where we can expect major
advances in our understanding of the pathogenesis of
asthma. This article is a highly personal view of what I
consider to be key developments that will affect asthma
treatment over the next decade.
Genetics of asthma
Although the mechanisms underlying the inflam›
matory response in the airways are still not fully under›
stood, it has become clear that both genetic
predisposition and subsequent environmental expo›
sure to allergen are integral to the development of the
disease. While studies of twins and families have shown
that asthma is a heritable disorder, it is clearly not a
disease caused by a single gene defect but rather a
polygenic disorder. It is only recently that studies look›
ing at which genes may predispose to the development
Possible future developments
• Genetic screening for “at risk” individuals
• Targeted gene therapy
• New therapeutic agents
• Immunisation approaches (such as anti›IgE anti›
bodies)
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of allergic disease have been performed. Two main
approaches have been used: genome screening and
identification of potential candidate genes.
Genome screening
In this approach the whole of the human genome is
screened by means of markers for regions of DNA
(microsatellites) that are highly variable between
individuals. By spreading microsatellite markers across
the whole of the human genome and looking for an
association with markers for allergic disease (such as
elevated IgE titres, bronchial hyperreactivity, atopy, or
clinical asthma), it is possible to identify genes that may
be important in defining each of these subphenotypes
of asthma.
In Britain and the United States genome screens
have recently been completed in populations of
patients with asthma, and genetic loci likely to be
important in the development of allergic disease have
been identified. At present, these regions of interest in
the genome are located only approximately, and the
fine mapping of these loci—essential to identify specific
genes rather than just regions of human chromo›
somes—will not be complete for another couple of
years. Nonetheless, this approach provides the best
hope of identifying novel gene products important in
the pathophysiology of asthma.
Candidate gene studies
The second approach is to identify potential candidate
genes which might be expected to be relevant to the
development of asthma (see box). This has the advan›
tage that if a causal association between a polymor›
phism or mutation within that gene and the clinical
marker for allergic disease is observed then fine
mapping will not be necessary.
One problem with this approach has been the
relatively small number of subjects included in many
studies (increasing the likelihood of false positive
results with borderline levels of significance). Another
critical point is that mutations or polymorphisms
within candidate genes or their promoter regions must
be functionally relevant if they are to be causally impli›
cated in the development of disease. Examples of can›
didate genes that have recently been examined in
detail are the â subunit of the high affinity IgE receptor
(FcåR1, situated on chromosome 11q)—in which (in
some populations) mutations have been identified—
and the â2 adrenoceptor (chromosome 5q)—for which
polymorphisms in the N terminal have been linked
with severity of disease in asthmatic populations. Both
of these receptors play important roles in controlling
airway responses, and hence functionally relevant
mutations would be expected to alter airway behaviour.
Technical developments
The ability to perform large genetics studies in
asthmatic populations has been radically improved
by the development of new techniques in molecular
genetics. Large scale assays based on the polymerase
chain reaction and automated screening of samples
have vastly increased the speed with which these stud›
ies may be performed. In addition, the production of
much more accurate physical maps of the human
genome as part of the human genome project has
made interpretation of data far easier.
One particularly useful development is the
establishment of an “expressed sequenced tagged”
database. Because most of the human genome is com›
posed of non›coding DNA (sometimes called junk
DNA) and only 5›10% of the genome codes for genes,
fine mapping, which involves screening large regions
of DNA for possible genes, has been time consuming.
The expressed sequenced tagged database identifies
short fragments of genes, which can then be placed
on a physical map of the relevant chromosome to
increase the speed with which candidate genes can be
identified.
Why is asthma genetics important?
If genes important for the development of asthma are
identified in the near future, what relevance will this
have to the way we care for asthmatic patients? Firstly,
knowing the gene products that are important in the
development of asthma will provide new potential tar›
gets for therapeutic intervention.
Secondly, it seems increasingly likely that early
intervention in high risk populations—before develop›
ment of asthma or perhaps at its earliest stage—may
prevent the development of chronic severe asthma and
the airway remodelling that accompanies it. If we can
define effective interventions (such as early avoidance
of allergens) for groups at risk then postnatal screening
may become both a practical and cost effective option.
Thirdly, although gene therapy would be inappro›
priate for most patients with asthma, it is conceivable
that this approach could be used in patients with severe
disease if potential targets for gene therapy have been
identified. The best targets may not be the genes that
predispose to the development of asthma but disease
modifying genes. Given the important role of airway
epithelium in chronic airway inflammation, and the
potential for topical administration of genes to the
lungs with aerosols, this approach is certainly feasible.
Two methods have been used to administer genes to
airway cells: first, with aerosols of DNA mixed with
charged fatty particles (liposomes), and, second, with
aerosols of a modified virus (such as adenovirus) in
which the gene of interest has been placed. However,
two major problems remain: firstly, obtaining
adequately high levels of expression of the gene of
interest in the airways and, secondly, preventing
inflammatory responses in the airways caused by
repeated administration of DNA contained in viral
based vectors.
Molecular basis of allergic inflammation
Th2 cytokines
Although genetic factors are important in determining
a person’s propensity to develop asthma, it is the inter›
Examples of potential candidate
genes for asthma
• Th2 cytokines (IL 4,5,9)
• â2 adrenoceptor polymorphisms
• High affinity IgE receptor (FcåR1)
• Tumour necrosis factor á
• 5›Lipoxygenase
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action of these genetic factors with environmental fac›
tors that determines the actual prevalence of the
disease. Numerous epidemiological studies over the
past 20 years have defined environmental factors that
are associated with an increased risk of developing
asthma—including a Western lifestyle, refined diet, early
exposure to allergen, maternal smoking, and patterns
of early childhood viral infection. Such studies tend to
provide observational rather than mechanistic infor›
mation.
Knowledge of potentially important mechanisms
has arisen as a result of advances in molecular cell biol›
ogy. It is clear that asthma is an inflammatory disease
characterised by up regulation of a specific subclass
of T helper cells (Th2) in the airways. Th2 driven
responses are found in atopic disease and are
associated with elevated expression of Th2 cytokines
(such as interleukin 4,5,9) and IgE mediated responses.
Initial attempts to characterise the important media›
tors driving this response were performed in animals.
Despite the existence of animal models such as ovalbu›
min sensitised guinea pigs and inbred strains of mice
and dogs with airway hyperresponsiveness, no animal
model with all the features of asthma has been
available. Partly because of this, over the past five years
many groups have performed bronchial biopsy studies
in asthmatic patients. Panels of antibodies have been
developed against the important cell surface markers,
enabling identification of subpopulations of different
inflammatory cells, and in situ hybridisation techniques
have allowed the mediators being produced by airway
cells to be defined. These developments have greatly
increased our understanding of the cytokine and
mediator networks underlying allergic inflammation in
the airways (fig 1).
It is now clear that Th2 cytokines play a crucial role
in both developing and sustaining airway inflamma›
tion in response to allergen exposure. Over the next
few years antagonists for these cytokines should
become available, allowing the individual importance
of each cytokine to be defined. The other approach
that has been used is to genetically engineer transgenic
mice in which the gene of interest is either
overexpressed or has been deleted (“knock outs”):
these animals are used as models for studying the roles
of individual cytokines.
Therapeutic approaches
Although studies of cytokines will be important in
defining the mechanisms underlying continued airway
inflammation, specific cytokines are not attractive as
therapeutic targets. Because there is redundancy in the
cytokine network, antagonists of an individual cytokine
may well be relatively ineffective on their own. It is clear
from biopsy studies that inhaled corticosteroids are
able to reduce numbers of inflammatory cells in
asthmatic airways and to reduce local production of
Th2 cytokines; thus, it is perhaps naive to imagine that
cytokine antagonists will be more effective as first line
treatments for asthma than inhaled corticosteroids.
To be truly effective, a therapeutic intervention
would have to target the initiating stage in the allergic
response. Interventions to reduce exposure to aller›
gens have had limited success. Critical questions that
require answering in this area are (a) why some foreign
proteins are so allergenic (such as Der p1, the major
allergen from the house dust mite), (b) what
mechanisms control the production of specific IgE in
response to allergen exposure, and (c) what the critical
antigen presenting mechanisms are in the airways.
Some data are becoming available to answer these
questions. For example, analysis of the crystal structure
of Der p1 suggests that its high allergenicity may be
related to its functioning as a protease. The next goal is
to identify regions in the molecule that are critical for
its biological activity, which might provide targets for
vaccine development.
Another therapeutic option currently being stud›
ied is to treat patients with anti›IgE antibodies in an
Fig 1 Some key pathways in airway inflammation in asthma
Fig 2 Key signal transduction pathways in airway cells. Agonists act at receptors coupled
to specific cell signalling pathways. R1: receptors coupled to phospholipase C (such as
histamine H1 receptors) elevate intracellular inositol 1,4,5 trisphosphate (IP3) and hence
cause a rise in intracellular calcium. R2: receptors positively (such as â2 adrenoceptors)
or negatively (such as muscarinic M2 receptors) coupled to adenylate cyclase cause rise
or fall in cyclic AMP levels. R3: receptors (such as epidermal growth factor receptors)
mediating the action of growth factors or cytokines stimulate a range of kinase pathways
to produce their effects on cell function
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attempt to damp down IgE mediated inflammatory
responses. The difficulty with this approach is that the
body may itself develop anti›idiotype antibodies
against the immunising antibody. None the less, this
kind of approach probably offers the best prospect for
a new first line treatment for asthma.
Mechanisms of cell activation
Cell surface receptors and intracellular second
messengers
A revolution has occurred in the past 15 years in
molecular pharmacology. New drugs used to be
discovered by screening compounds for biological
activity on animal tissue preparations in organ baths.
Now, most primary screening of compounds is done
with cell culture systems. Cell surface receptors
responsible for transducing the effect of many classic
agonists and antagonists to the cell have been
identified and cloned. By expressing these receptors in
cell lines that do not constitutively express the relevant
cell surface receptors, the function of individual recep›
tor subtypes can be clearly defined. These cell lines can
then be used to screen lead compounds for activity at
individual receptor subtypes. For example, selectivity
for â2 adrenoceptor stimulation could be studied with
three cell lines expressing â1, â2,or â3 receptors.
In order to perform these kind of studies a simple
readout of receptor activation is required. Many
important airway receptors are coupled to one of two
major signal transduction pathways, generating intra›
cellular second messengers that mediate the effect of
drugs acting on these receptors. These two pathways
involve either the activation of phospholipase C or of
adenylate cyclase, resulting respectively in a rise in
inositol 1,4,5, trisphosphate (and hence intracellular
calcium) or cyclic AMP within the cell (fig 2). A rise in
intracellular calcium can stimulate mediator release,
cell activation, or contraction depending upon the cell
type under consideration (fig 3). In contrast, elevation
of cyclic AMP levels generally inhibits cell activation—
for example, producing relaxation of smooth muscle
cells. In addition, some receptors are negatively
coupled to adenylate cyclase and can reduce levels of
intracellular cyclic AMP. This kind of approach is, of
course, not limited to cell surface receptors but can also
be used to identify drugs acting at other sites by using
appropriate readouts of activation (see box).
Molecular modelling and drug design
Molecular pharmacological techniques have also
produced a wealth of information on the mechanisms
underlying activation of receptors and their interaction
with drugs. The most powerful approach in this area
has been to use site directed mutagenesis or chimeric
receptor techniques to alter one or a few amino acids
within a given receptor and then to study the
characteristics of the altered receptor in cell lines. Such
studies require the manipulation of the cDNA for the
receptor to specifically alter bases to change the amino
acid sequence of the receptor so that the mutated
receptor can be expressed in a cell line. The approach
is important because it allows the definition of critical
parts of receptor molecules for binding of agonists and
antagonists. For example, it has been used to deter›
mine the mechanism underlying the long duration of
action of salmeterol in the airways: this seems to be due
to interaction of the long side chain of the molecule
with specific amino acid residues in the fourth
transmembrane spanning domain of the â2 receptor.
By determining critical sites for interaction within
the receptor drug complex with molecular modelling
techniques, the precise molecular characteristics
required of a biologically active compound can be
identified and lead compounds designed. Conceptu›
ally, this “reverse pharmacology” is the opposite of
drug screening.
Understanding cell signalling pathways is also
important in discovering how cells are activated, both
by endogenous mediators such as cytokines and by
Potential therapeutic targets in the
airways
• Phosphodiesterase isoforms
• K + channels
• Muscarinic receptors (such as M3)
• Leukotriene receptors (such as LTD4)
• 5›Lipoxygenase
• Th2 cytokine receptors
• Receptors for cell adhesion molecules
Fig 3 Intracellular calcium changes in response to an agonist in
smooth muscle cell line loaded with the calcium sensitive dye
Fura 2: changes in fluorescence signal in individual cells are
shown in pseudocolour (blue=low calcium, red=high calcium)
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environmental stimuli that can worsen asthma. For
example, epidemiological studies have shown that
ozone, particulates, and nitrogen oxides may worsen
asthma. The mechanism underlying this effect can be
studied with cells in culture by looking at the signalling
events after exposure to pollutants. Another example is
in the study of non›cytokine mediators. Of particular
current interest are nitric oxide and oxygen›free
radicals. Nitric oxide is released from epithelial cells
and inflammatory cells and may have an anti›
inflammatory role in the airways, whereas oxygen›free
radicals are produced by activated inflammatory cells
(such as eosinophils) and may have cytotoxic effects.
Unravelling the signalling pathways involved in the
release of these mediators, and the pathways involved
in their effects on target cells, will help define the role
of these agents in more detail and may provide new
therapeutic targets in asthma.
Control of cell proliferation
While short term responses in airway cells are depend›
ent on short lived second messengers, longer term
effects such as cell proliferation are dependent on acti›
vation of other signal transduction pathways such as
the MAP (mitogen activated) kinase cascade, which in
2turn increase expression of genes important in
progression of the cell cycle. Complex interactions
between the different parts of this cascade and other
intracellular signalling pathways dictate the ultimate
degree of proliferation (and hence remodelling) that
occurs in the airways. Many of the longer term effects
of corticosteroids are likely to be mediated through
inhibitory effects on these pathways. At present,
however, no therapeutic compounds targeted specifi›
cally at transcriptional activation in airway cells exist,
and it is difficult to see how cell specificity could be
effected with such a target.
Conclusions
In this review I have highlighted some of the ways in
which advances in basic scientific research have led to
increased understanding of the mechanisms underly›
ing the physiopathology of asthma. Why is it important
for clinicians to know about changing approaches to
the study of asthma?
Firstly, it is important that we are able to evaluate
the importance of advances in asthma research.
Secondly, we need to be able to evaluate the likely
importance of new therapeutic drugs. Examples of
drugs in the late stage of development include
5›lipoxygenase inhibitors, leukotriene D4 receptor
antagonists, and isoform selective phosphodiesterase
inhibitors. Each of these classes of drugs will need
evaluating against a broad knowledge of the impor›
tance of their targets in the pathophysiology of asthma.
Thirdly, awareness of current research is crucial in the
design of future studies. For example, if the preliminary
studies implicating â2 adrenoceptor polymorphisms in
determining airway responses to â2 agonists prove to
be correct, clinical studies involving these drugs will
need to take this genetic variable into consideration
when randomising patients. Finally, and perhaps most
importantly, high quality asthma research in the future
requires a combination of a knowledge of clinical
asthma together with an understanding of the basic
scientific approaches to studying complex disease.
Clinical scientists are ideally placed to use techniques
of modern molecular medicine to answer focused
questions in asthma research.
Funding: IPH is funded by the National Asthma Campaign
as a senior research fellow.
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WHEN I USE A WORD . . .
Shalom Salmonella
An outbreak of diarrhoea caused, I’m told, by small round structured
viruses, reminded me of the time when we admitted several people
with acute diarrhoea. They had all eaten salmon from the cold buffet
at a wedding. It must be due to salmonella, I told the students. To their
credit they didn’t believe me; it turned out to be Escherichia coli. Of
course, you can catch salmonella from salmon, but not etymologically.
The Greeks used a sign that we call a breathing over a vowel at
the start of a word. A sign that looked like a comma, a smooth
breathing, was not pronounced. In contrast, a reversed comma, a
rough breathing, was aspirated, as we would pronounce the letter h. In
Latin, this rough breathing was replaced by the letter s. For example,
salt in Greek was [h]als (whence halide); in Latin sal (saline). In Greek
six was [h]ex (hexameter); in Latin sex (sextet, the last six lines of a
sonnet). Now, the Greek word meaning to leap was [h]allomai, from
which we get halma, a game in which the men jump over one another.
The Latin equivalent was salire, whence the name of the leaping fish
salmo (English salmon).
The word salmonella, on the other hand, was coined by the
Frenchman J LigniŁres in 1900, after the American pathologist Daniel
Elmer Salmon (1850›1914). But Salmon’s name has nothing to do
with the fish. It is one of several corruptions (including Salman,
Salmond, and Sammons) of the name Solomon, which in turn comes
from the Hebrew word shalom, peace. In II Samuel (12:25) it is
recounted how Bathsheba bore a son and how the prophet Nathan
called him Jedidiah (beloved of God); but according to the prophet of
I Chronicles (22:9), God appeared to David in a dream and told him
to call the boy Shlomoh (peaceful one). So, Salman Rushdie is a
Solomon, although not perhaps wise in the eyes of his Islamic
brethren.
Shalom in Hebrew is equivalent to salaam in Arabic, both used as
greetings, from the phrase "peace be with you" (shalom aleikhem or
salaam aleikum). A salaam fit, first described by Sir Charles Clarke
(1752›1857) and nowadays called infantile spasm, consists of a
movement of the arms reminiscent of the movement of making a
salaam in greeting. Not a very peaceful type of problem.
Jeff Aronson is a clinical pharmacologist in Oxford
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Lesson of the Week
Penetrating intra›oral trauma in children
Robert C Law, Claire A Fouque, Angus Waddell, Eleri Cusick
The incidence of penetrating intra›oral trauma in chil›
dren is unknown and most cases probably heal sponta›
neously without being seen by doctors.1 Occasionally
these children develop acute life threatening complica›
tions. Retropharyngeal and mediastinal abscesses,
mediastinitis, widespread emphysema, internal carotid
artery thrombosis, and airway obstruction have all
been reported. We recently treated two children with
mediastinal sepsis after intra›oral injuries caused by
toothbrushes.
Case reports
Case 1
A 13 month old girl presented to the accident and
emergency department within two hours of an
unwitnessed fall from a standing position with her
toothbrush in her mouth. She looked well, with no res›
piratory distress or stridor but was noted to have a 1 cm
abrasion to her right anterior faucial pillar. The tonsil
was not pushed towards the midline, as occurs in peri›
tonsillar abscess or bleeding lateral to the tonsillar bed.
She was discharged home without treatment but
returned to hospital 24 hours later with severe inspira›
tory and expiratory stridor and severely swollen cervi›
cal soft tissues. Radiography showed cervical surgical
emphysema, a pneumomediastinum, widening of the
prevertebral tissues displacing the trachea anteriorly,
and a left pneumothorax.
Her trachea was intubated after gaseous induction,
and an examination under anaesthesia showed a retro›
pharyngeal abscess draining into the base of the right
pyriform fossa. A right sided neck exploration was per›
formed, the abscess was drained percutaneously, and a
left sided intercostal drain inserted.
She was transferred to the intensive care unit,
where she was mechanically ventilated for a week and
treated with intravenous cefotaxime, penicillin, metro›
nidazole, and fluconazole. The culture swab sent from
the operating theatre grew pneumococci, Haemophilus
influenzae, and yeasts.
She remained feverish, and a right thoracotomy
was performed to drain an abscess extending from the
posterior oropharynx into the right superior mediasti›
num. The mediastinal collection did not recur, but she
required four further neck explorations to drain
retropharyngeal collections. She initially received
parenteral nutrition but subsequently was fed through
a nasogastric tube and then by percutaneous
gastrostomy. She was discharged home nine weeks
after the injury and was well at the time of writing.
Case 2
A 2 year old girl was brought to the accident and emer›
gency department after a fall down a flight of stairs
with an adult toothbrush in her mouth. This was pulled
out by her mother, resulting in some bleeding. The
only finding on examination was a small laceration of
the soft palate, and she was discharged without
treatment. Her parents remained concerned, however,
and refused to leave the department.
Over the next two hours she became unwell and
was noted to be drooling saliva and to have a swollen
neck and poor peripheral perfusion; oxygen saturation
varied considerably according to her head position.
She was intubated easily after an intravenous induction
and was transferred to the intensive care unit. She
developed cervical surgical emphysema and right
upper lobe collapse but no pneumomediastinum or
pneumothorax. Examination under anaesthesia
showed a 2 cm full thickness longitudinal tear in the
left pyriform fossa, extending down into the superior
mediastinum. A nasogastric tube was inserted under
direct vision and placed on continuous suction. She
was initially fed parenterally and was given intravenous
cefuroxime, gentamicin, metronidazole, and flucona›
zole.
She developed mediastinitis and acute lung injury
and required three weeks of mechanically assisted ven›
tilation. Despite a persistent fever no organism was cul›
tured and no focal collections required surgical
drainage. She was discharged home four weeks after
injury and remained well.
Discussion
Children often put sharp objects in their mouths. The
most common items responsible for injuries include
toothbrushes, toys, sticks, pens, and pencils, and, in
Asia, chopsticks.2›4 Injuries are most likely to be
sustained by toddlers who are still unsteady on their
feet and fall on to the object.2›4 There is a reported
strong male predominance.3 4 Injuries tend to occur in
the posterolateral oropharynx, and initial symptoms
are usually limited to minor oral bleeding.2 4
Several anatomical points are important. The
prevertebral fascia divides into two layers in front of
the vertebrae: the anterior layer, or alar part, and the
posterior layer, or prevertebral part. The alar part fuses
with connective tissue on the posterior surface of the
oesophagus, thus limiting the retrovisceral space
largely to the neck. The more dorsal space between the
two layers of prevertebral fascia (danger space) extends
from the base of the skull to the diaphragm and may be
important in allowing infections to spread into the
mediastinum. The carotid artery lies lateral to the
tonsil.5
One major complication of penetrating pharyn›
geal injury is infection with abscess formation or medi›
astinitis, or both.1 2 Both of our patients developed
mediastinal infection secondary to soiling of the retro›
pharyngeal space. In case 1 there were localised
abscesses in both the retropharyngeal space and medi›
astinum and extensive mediastinal emphysema; medi›
astinitis and a secondary acute lung injury developed
in case 2.
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Another serious complication is airway obstruction
as a result of emphysema or abscesses.1 2 In both cases
the airway was compromised and required intubation.
This was largely due to surgical emphysema, which in
case 1, was further complicated by anterior displace›
ment of the posterior pharyngeal wall.
Carotid thrombosis is a rare complication occa›
sionally seen in injuries of this kind.4 6 This is believed
to follow an intimal tear caused by compression of the
artery against the cervical vertebrae at the time of the
injury.7 The clot may propagate distally and result in
widespread cerebral infarction. Classic symptoms are
an initial lucid interval followed by deterioration in
consciousness level, hemiplegia, and aphasia.2
The potential for rare life threatening delayed
complications has led to uncertainty about optimal
early management. Patients with symptoms must be
admitted to hospital, but the management of the
larger, symptom free population remains controver›
sial. Some suggest admission for only those with lateral
injury or retropharyngeal trauma because they are
most at risk of adverse sequelae.1 Others conclude that
all symptom free children should be managed at home
and their parents instructed which symptoms should
prompt a return to hospital.3 4 These conclusions were
based on the observation that serious complications
were rare and may develop even after discharge
following a 48 hour admission.
Three retrospective reviews of penetrating oropha›
ryngeal trauma in children have been published.2›4
Hellman et al described 131 hospital admissions. Their
only complication was one case of facial cellulitis. Rad›
kowski et al reviewed 23 cases that required hospital
admission. Complications included one case of buccal
cellulitis, one pneumomediastinum which resolved
spontaneously, and one case of pneumonia.3 Kosaki et
al reported on 12 patients, three of whom developed
complications and were admitted2; the nine others
were treated as outpatients. One patient developed
surgical emphysema, one developed subcutaneous,
mediastinal, and retropharyngeal emphysema, and
one developed a retropharyngeal abscess requiring
surgical drainage.
Care must be taken to ensure that patients who are
discharged are able to eat and drink. In inpatients
enteral feeding is widely accepted as being preferable
to parenteral nutrition, but the risk of gastro›
oesophageal reflux, leading to further contamination
of the wound, needs to be considered. There is no con›
sensus on the need for antibiotics or surgical explora›
tion in uncomplicated cases, although the urge to
suture minor wounds should be resisted.1 8
Each of the children we have described here was
initially discharged. Hospital staff need to know about
the potential complications of such penetrating
injuries and be aware that symptoms may be rapid in
onset and life threatening. If symptom free children are
discharged home parents need to be instructed to
observe their child closely for 72 hours and should be
given a list of specific symptoms to look out for.4
We feel that, as the complications of these injuries
may be so devastating, parents need to be made aware
of the dangers of allowing toddlers to walk around with
sharp objects in their mouths. Toothbrushing must be
supervised, and although dental hygiene should be
encouraged, toothbrushes must not be presented as
toys. We have asked toothbrush manufacturers to place
a warning on toothbrush packaging, and several lead›
ing companies will be amending their packaging in the
near future.
1 Singer J. Management strategy for penetrating oropharyngeal injury.
Pediatr Emerg Care 1989;5:250›2.
2 Kosaki H, Nakamura N, Toriyama Y. Penetrating injuries to the orophar›
ynx. J Laryngol Otol 1992;106:813›16.
3 Radkowski D, McGill TJ, Healy GB, Dwight TJ. Penetrating trauma of the
oropharynx in children. Laryngoscope 1993;103:991›4.
4 Hellmann JR, Shott SR, Gootee MJ. Impalement injuries of the palate in
children: review of 131 cases. Int J Pediatr Otorhinolaryngol 1993;26:157›
63.
5 Hollinshead WF. Anatomy for surgeons. 2nd ed. New York: Harper and
Row, 1968.
6 Bickerstaff ER. Aetiology of acute hemiplegia in childhood. BMJ 1964;
2:82›7.
7 Higgins GL, Meredith JT. Internal carotid artery thrombosis following
penetrating trauma of the soft palate; an injury of youth. J Fam Pract
1991;32:316›22.
8 Dolgin SR, Kumar NR, Wykoff TW, Maniglia AJ. Conservative medical
management of traumatic pharyngoesophageal perforations. Ann Otol
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Fig 1 Sagittal and horizontal sections of the neck showing
division of prevertebral fascia. (Sagittal section is based on figs
5›9 and 5›11 from Hollinshead5 and is adapted by permission of
Wiley›Liss. Horizontal section is redrawn from fig 5›5 of
Hollinshead5 and is reproduced by permission of Lippincott›Raven)
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